Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Mergers and Acquisitions